{"id":180,"date":"2009-11-15T02:00:14","date_gmt":"2009-11-14T17:00:14","guid":{"rendered":"http:\/\/preview-me.net\/m.ehime-u.ac.jp\/school\/radiology\/?post_type=results&p=180"},"modified":"2020-12-16T20:45:33","modified_gmt":"2020-12-16T11:45:33","slug":"2008%e5%b9%b4%e5%ba%a6","status":"publish","type":"results","link":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/results\/180\/","title":{"rendered":"2008\u5e74\u5ea6"},"content":{"rendered":"

\u25a0 \u8ad6\u6587\u30fb\u8457\u66f8
\n\u539f\u8457\u8ad6\u6587<\/a>
\n\u7dcf\u8aac\uff0c\u4ed6<\/a>
\n\u75c7\u4f8b\u5831\u544a<\/a>
\n\u8457\u66f8<\/a>
\n\u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868
\n\u56fd\u969b\u5b66\u4f1a<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/a>
\n\u25a0 \u8b1b\u6f14<\/a>
\n\u25a0 \u7814\u7a76\u52a9\u6210\u30fb\u4ed6<\/a><\/p>\n

—————————<\/p>\n

\u25a0<\/span> \u8ad6\u6587\u30fb\u8457\u66f8<\/strong><\/p>\n

<\/a>\u25cf<\/span> \u539f\u8457\u8ad6\u6587<\/p>\n

1. Nishizawa S, Inubushi M, Kido A, Miyagawa M, Inoue T, Shinohara K, Kajihara M. Incidence and characteristics of uterine leiomyomas with FDG uptake. Ann Nucl Med 22: 803-810, 2008\u3000 [PubMed]<\/a>
\n2. Sakata K,Sakurai H, Suzuki Y, Katoh S, Ohno T, Toita T, Kataoka M, Tanaka E, Kaneyasu Y, Uno T, Harima Y, Nakano T. Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: Study of JROSG (Japan Radiation Oncology Study Group). Act Oncologica 47: 434-441, 2008\u3000 [PubMed]<\/a>
\n3. Tagashira H, Arakawa K, Yoshimoto M, Mochizuki T, Murase K, Yoshida H. Improvement of lung abnormality detection in computed radiography using multi-objective frequency processing: Evaluation by receiver operating characteristics (ROC) analysis. Eur J Radiol. 65: 473-7, 2008\u3000 [PubMed]<\/a>
\n4. Hashine K, Miura N, Numata K, Shirato A, Sumiyoshi Y, Kataoka M. Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Int J Uro 15: 403-406, 2008\u3000 [PubMed]<\/a>
\n5. Miura N, Kusuhara Y, Numata K, Shirato A, Hashine K, Sumiyoshi Y, Kataoka M, Takechi S. Radiation Pneumonitis Caused by a Migrated Brachytherapy Seed Lodged in the Lung. Jpn J Clin Oncol 38: 623-625, 2008\u3000 [PubMed]<\/a>
\n6. Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M. A Prospective Longitudinal Study Comparing a Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy Regarding the Health-related Quality of Life for Localized Prostate Cancer. Jpn J Clin Oncol 38: 480-485\u3000 [PubMed]<\/a>
\n7. Kido T, Kurata A, Inoue Y, Higashino H, Mochizuki T. Quantification of Regional Myocardial Blood Flow Using First-Pass Multidetector-Row Computed Tomography and Adenosine Triphosphate in Coronary Artery Disease. Circ J 72: 1086-1091, 2008\u3000 [PubMed]<\/a>
\n8. Hiratsuka Y, Miki H, Kiriyama I, Kikuchi K, Takahashi S, Matsubara I, Sadamoto K, Mochizuki T. Diagnosis of Unruptured Intracranial Aneurysms: 3T MR Angiography versus 64-channel Multi-detector Row CT Angiography. Magn Reson Med Sci. 7:169-178, 2008\u3000 [PubMed]<\/a>
\n9. Nagao M, Higashino H, Matsuoka H, Kawakami H, Mochizuki T, Murase K, Uemura M, Kouno T. Clinical importance of microvascular obstruction on contrast-enhanced MRI in reperfused acute myocardial infarction. Circ J 72: 200-204, 2008\u3000 [PubMed]<\/a>
\n10. Nagao M, Matsuoka H, Kawakami H, Higashino H, Mochizuki T, Murase K, Uemura M. Quantification of myocardial perfusion by contrast-enhanced 64-MDCT: characterization of ischemic myocardium. Am J Roentgenol 191:19-25, 2008\u3000 [PubMed]<\/a>
\n11. Nagao M, Higashino H, Matsuoka H, Kawakami H, Mochizuki T, Uemura M, Tokunaga N, Murase K. Analysis of microvascularity after reperfused acute myocardial infarction using the maximum slope method of contrast-enhanced magnetic resonance imaging. Radiat Med 26: 296-304, 2008\u3000 [PubMed]<\/a>
\n12. \u6c60\u7530\u3000\u6062\uff0c\u897f\u5c3e\u6b63\u9053\uff0c\u7247\u5ca1\u6b63\u660e\uff0c\u677e\u672c\u5eb7\u7537\uff0c\u5e61\u91ce\u548c\u7537\uff0c\u837b\u91ce\u3000\u5c1a\uff0c\u52a0\u8cc0\u7f8e\u82b3\u548c. \u653e\u5c04\u7dda\u6cbb\u7642\u304b\u3089\u307f\u305f\u304c\u3093\u8a3a\u7642\u9023\u643a\u62e0\u70b9\u75c5\u9662 \uff0dJASTRO\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u306b\u3088\u308b\u5206\u6790\uff0d. \u65e5\u653e\u816b\u4f1a\u8a8c 20: 13-22, 2008\u3000 [J-STAGE]<\/a>
\n13. \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3CT\u306e\u65b0\u3057\u3044\u64ae\u5f71\u6cd5 \u2013Step and Shoot Cardiac\u306e\u81e8\u5e8a\u7d4c\u9a13. \u30a4\u30f3\u30ca\u30fc\u30d3\u30b8\u30e7\u30f3 23(8): 92-95, 2008\u3000 [Medical Online]<\/a>
\n14. \u5009\u7530\u8056, \u57ce\u6238\u8f1d\u4ec1, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u4ed6. \u5e0c\u91c8\u9020\u5f71\u5264\u306b\u3088\u308btest injection\u6cd5\u3092\u7528\u3044\u305f\u51a0\u52d5\u8108CT angiography\u64ae\u50cf\u30bf\u30a4\u30df\u30f3\u30b0\u306e\u6700\u9069\u5316. \u6620\u50cf\u60c5\u5831Medical 40: 662-667, 2008\u3000 [Medical Online]<\/a>
\n15. \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u5e0c\u91c8\u9020\u5f71\u6cd5\u3092\u7528\u3044\u305f\u5fc3\u81d3CT\u3000\u51a0\u52d5\u8108\u9020\u5f71\u52b9\u679c\u6a19\u6e96\u5316\u306e\u8a66\u307f. \u6620\u50cf\u60c5\u5831Medical 40(11): 1042-1046, 2008\u3000 [Medical Online]<\/a><\/p>\n

<\/a>\u25cf<\/span> \u7dcf\u8aac\uff0c\u4ed6<\/p>\n

1.\t\u6771\u91ce \u535a, \u4e95\u4e0a \u7950\u99ac, \u9f4b\u85e4 \u5b9f,\u5ca1\u5c71 \u82f1\u6a39, \u6a9c\u57a3 \u5be6\u7537, \u4e09\u6728 \u5747, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b \u5fd7\u6d25\u6c5f, \u6c5f\u539f \u79c0\u5b9f, \u8c9e\u672c \u548c\u5f66. 3T-MRI\u306b\u3088\u308b\u5fc3\u81d3MRI \u73fe\u72b6\u3068\u4eca\u5f8c\u306e\u8ab2\u984c. \u6620\u50cf\u60c5\u5831Medical 40: 28-33, 2008
\n2.\t\u6771\u91ce \u535a, \u9f4b\u85e4 \u5b9f,\u4e95\u4e0a \u7950\u99ac,\u5ca1\u5c71 \u82f1\u6a39, \u6a9c\u57a3 \u5be6\u7537, \u4e09\u6728 \u5747, \u671b\u6708\u8f1d\u4e00, \u6c5f\u539f \u79c0\u5b9f, \u8c9e\u672c \u548c\u5f66. 3T\u88c5\u7f6e\u3092\u7528\u3044\u305f\u5fc3\u81d3MRI. \u81e8\u5e8a\u653e\u5c04\u7dda 53: 164-173, 2008
\n3.\t\u6771\u91ce \u535a, \u671b\u6708 \u8f1d\u4e00. 3T MRI \u5fc3\u81d3\u306eMRI. \u6620\u50cf\u60c5\u5831Medical 40: 892-897, 2008
\n4.\t\u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u865a\u8840\u6027\u5fc3\u75be\u60a3\u306b\u304a\u3051\u308b\u51a0\u52d5\u8108\u75c5\u5909\u306e\u753b\u50cf\u8a3a\u65ad. \u8840\u6813\u3068\u5faa\u74b0 15: 244-248
\n5.\t\u6771\u91ce \u535a. Cardiac Imaging 2008 \u5fc3\u81d3MRI\u306e\u73fe\u72b6\u3068\u6700\u524d\u7dda. \u81e8\u5e8a\u753b\u50cf 24: 136-145, 2008
\n6.\t\u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u5faa\u74b0\u5668\u5c02\u9580\u533b\u306b\u5fc5\u8981\u306a\u77e5\u8b58\uff0fCT\u3068MRI\u306e\u9032\u6b69. Heart View 12: 129-132, 2008
\n7.\t\u4e95\u4e0a\u7950\u99ac, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3MRI-\u30eb\u30fc\u30c1\u30f3\u64ae\u50cf\u3092\u4e2d\u5fc3\u306b. \u30a4\u30f3\u30ca\u30fc\u30d3\u30b8\u30e7\u30f3 23: 18-23, 2008
\n8.\t\u8352\u672c\u5b5d\u826f, \u5bae\u5ddd\u6b63\u7537, \u4ed6. \u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u3000cN0\u75c7\u4f8b\u306b\u304a\u3051\u308bFDG PET-CT\u3068\u30bb\u30f3\u30c1\u30cd\u30eb\u30ea\u30f3\u30d1\u7bc0\u751f\u691c\u306e\u610f\u7fa9. \u982d\u981a\u90e8\u764c 34: , 2008
\n9.\t\u6771\u91ce \u535a. \u7279\u96c61 \u6838\u533b\u5b66\u306e\u6700\u524d\u7dda Part 2 \u9032\u5316\u3059\u308b\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2 Clinical Report \u653e\u5c04\u7dda\u79d1\u533b\u306b\u3068\u3063\u3066\u306e\u5fc3\u81d3\u6838\u533b\u5b66 – CardioNAVI\u306e\u6709\u7528\u6027 \u2013 Rad Fan 6: 40-42, 2008<\/p>\n

<\/a>\u25cf<\/span> \u75c7\u4f8b\u5831\u544a<\/p>\n

10.\tSakayama K, Tauchi H, Sugawara Y, Kidani T, Tokuda K, Miyazaki T, Watanabe Y, Yamamoto H. A complete remission of sclerosing rhabdomyosarcoma with multiple lung and bone metastases treated with multi-agent chemotherapy and peripheral blood stem cell transplantation (PBSCT): a case report. Anticancer Res 28: 2361-2367, 2008
\n11.\t\u57ce\u6238\u8f1d\u4ec1. Case of The Month\u300c\u5fc3\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u300d\u753b\u50cf\u8a3a\u65ad 28: 833-836, 2008
\n12.\t\u57ce\u6238\u8f1d\u4ec1. Case of The Month\u300c\u5ddd\u5d0e\u75c5\u5f8c\u907a\u75c7\u51a0\u52d5\u8108\u7624\u300d\u753b\u50cf\u8a3a\u65ad 28: 1094-1096, 2008
\n13.\t\u4e95\u4e0a\u7950\u99ac, \u671b\u6708\u8f1d\u4e00. Case of The Month\u300c\u51a0\u52d5\u8108\u763b\u300d\u753b\u50cf\u8a3a\u65ad 28: 1093, 2008
\n14.\t\u57ce\u6238\u8f1d\u4ec1. Case of The Month\u300c\u5fc3\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u300d\u306e\u89e3\u7b54 \u753b\u50cf\u8a3a\u65ad 28: 1094-1095, 2008
\n15.\t\u5009\u7530 \u8056. Case of The Month\u300c\u920d\u7684\u5916\u50b7\u306b\u3088\u308b\u4e09\u5c16\u5f01\u9589\u9396\u4e0d\u5168\u300d\u753b\u50cf\u8a3a\u65ad 28: 1229, 2008
\n16.\t\u57ce\u6238\u8f1d\u4ec1. Case of The Month\u300c\u5ddd\u5d0e\u75c5\u5f8c\u907a\u75c7\u51a0\u52d5\u8108\u7624\u300d\u306e\u89e3\u7b54 \u753b\u50cf\u8a3a\u65ad 28: 1230-1231, 2008
\n17.\t\u7d30\u5ddd\u6d69\u5e73. Case of The Month\u300cARVC\u300d\u753b\u50cf\u8a3a\u65ad 28: 1367, 2008
\n18.\t\u4e95\u4e0a\u7950\u99ac, \u671b\u6708\u8f1d\u4e00. Case of The Month\u300c\u51a0\u52d5\u8108\u763b\u300d\u306e\u89e3\u7b54 \u753b\u50cf\u8a3a\u65ad 28: 1368-1370, 2008
\n19.\t\u4e95\u4e0a\u7950\u99ac, \u671b\u6708\u8f1d\u4e00. Case of The Month\u300c????\u300d\u753b\u50cf\u8a3a\u65ad 28: 1483, 2008
\n20.\t\u5009\u7530 \u8056. Case of The Month\u300c\u920d\u7684\u5916\u50b7\u306b\u3088\u308b\u4e09\u5c16\u5f01\u9589\u9396\u4e0d\u5168\u300d\u306e\u89e3\u7b54 \u753b\u50cf\u8a3a\u65ad 28: 1484-1486, 2008
\n21.\t\u4e95\u4e0a\u7950\u99ac, \u671b\u6708\u8f1d\u4e00. M-pos\u3000\u5185\u819c\u4e0b\u6897\u585e Rad Fan 6: 6-7, 2008
\n22.\t\u4e95\u4e0a\u7950\u99ac, \u671b\u6708\u8f1d\u4e00. M-pos\u3000MO(microvascular obstruction)\u3092\u4f34\u3046\u8cab\u58c1\u6027\u6897\u585e Rad Fan 6: 8-9, 2008<\/p>\n

<\/a>\u25cf<\/span> \u8457\u66f8
\n23.\t\u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u5148\u5929\u6027\u5fc3\u30fb\u5927\u8840\u7ba1\u7cfb\u75be\u60a3\u300c\u80ba\u9759\u8108\u72ed\u7a84\u75c7,\u80ba\u9759\u8108\u9589\u585e\u75c7\u300d\u65e5\u672c\u81e8\u5e8a\u5225\u518a \u5faa\u74b0\u5668\u75c7\u5019\u7fa4\uff08\u7b2c2\u7248\uff09\u2163: 234-238, 2008<\/p>\n

\u25a0<\/span> \u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868<\/strong><\/p>\n

<\/a>\u25cf<\/span> \u56fd\u969b\u5b66\u4f1a<\/p>\n

24.\tI.Kiriyama, H. Miki, Y. Hiratsuka, K.Kikuchi, T.Mochizuki. Surface anatomy of Inferior Parietal Lobule in high resolution three-dimensional MRI. ECR2008 (2008. 3, Vienna)
\n25.\tI.Kiriyama, H. Miki, Y. Hiratsuka, K.Kikuchi, T.Mochizuki. Investigation of optimal volume rendering image in brain surface with high resolution three-dimensional MRI. ECR2008 (2008. 3, Vienna)
\n26.\tKurata A, Kido T, Inoue Y, Hosokawa K, Higashino H, Mochizuki T. Adenosine Triphosphate Stress Myocardial Perfusion CT in Differential Diagnosis of Myocardial Ischemia and Infarction. SCCT2008 (2008.3, Orland)
\n27.\tKurata A, Kido T, Inoue Y, Hosokawa K, Higashino H, Mochizuki T. Optimal Scan Timing for Coronary 64-slice CT Angiography Using Test Bolus of the Diluted Contrast Medium. Annual Congress of Asian Society of Cardiovascular Imaging. (2008.4, Singapore)
\n28.\tMiki H, Kiriyama I, Hiratsuka Y, Kikuchi K, Mochizuki T. Topographic Analysis of Brain Surface with High Resolution 3D-MRI. \u7b2c14\u56de\u65e5\u72ec\u653e\u5c04\u7dda\u533b\u5b66\u4ea4\u6d41\u8a08\u753b \uff082008.5, Dresden\uff09
\n29.\tHiratsuka Y, Miki H, Kikuchi K, Kiriyama I, Mochizuki T, Takahashi S, Matsubara I, Sadamoto K. Evaluation of unraptured Intracranial aneurysma with 3T 3D TOF MRA; Comparison of 64-MDCTA. 16th ISMRM (Tront, 2008. 5)
\n30.\tSogabe I, Ishimaru Y, Kogame M, Kajihara M, Matsuki I, Kikuchi T, Nakamura S, Miyagawa M, Tanaka H, Hirata M, Mochizuki T. Usefulness of 3D MR angiography for pre-angioplasty evaluation of hemodialysis arteriovenous fistula and graft. 8th APCCVIR 2008 (Kuala Lumpur, 2008.6)
\n31.\tHamamoto Y, Kataoka M. Changes of treatment outcome of stage III non-small cell lung cancer treated with concurrent chemoradiotherapy in the single institution. 27th European Society for Therapeutic Radiation Oncology (Goeteborg, Sweden, 2008.9)
\n32.\tS.Kumano, M.Okada, T.Hyodo, T.Tsuda, T.Mochizuki,T.Murakami. Contrast-enhanced MRI and CT for Biliary System: Advantage and Pitfall of Imaging with Gd-EOB-DTPA and Iotroxic Acid Meglumine. 94th RSNA (2008. 11, Chicago)
\n33.\tNagao M, Uemura M, Higashino H, Mochizuki T, et al. Evaluation of coronary artery disease with fusion of coronary tree and myocardial perfusion on contrast-enhanced 64-slice MDCT 94th RSNA (2008. 11, Chicago)
\n34.\tKurata A, Kido T, Inoue Y, Hosokawa K, Higashino H, Mochizuki T. Adenosine Triphosphate Stress Myocardial Perfusion CT in Comparison With SPECT and MRI. AHA2008 (2008.11. New Orleans)<\/p>\n

<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09<\/p>\n

35.\t\u4e95\u4e0a\u7950\u99ac, \u7d30\u5ddd\u6d69\u5e73, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00. \u5e0c\u91c8\u9020\u5f71\u5264\u3092\u7528\u3044\u305f test bolus \u6cd5\u306b\u3088\u308b\u5fc3\u81d3\u30de\u30eb\u30c1\u30b9\u30e9\u30a4\u30b9 CT \u64ae\u50cf\u306e\u6a19\u6e96\u5316. \u7b2c66\u56de \u5fc3\u81d3\u8840\u7ba1\u7814\u7a76\u4f1a (2008.1, \u6d25)
\n36.\t\u4e09\u6728\u3000\u5747, \u6850\u5c71\u3000\u90c1\u5b50, \u5e73\u585a\u7fa9\u5eb7, \u83ca\u6c60\u6075\u4e00, \u671b\u6708\u8f1d\u4e00. \u4e09\u6b21\u5143MRI\u306b\u3088\u308b\u8133\u8868\u30dc\u30ea\u30e5\u30fc\u30e0\u30ec\u30f3\u30c0\u30ea\u30f3\u30b0\u753b\u50cf\uff1a\u4e0d\u900f\u660e\u5ea6\u306e\u6700\u9069\u5316. \u7b2c13\u56de3\u6b21\u5143CT\u30fbMRI\u7814\u7a76\u4f1a\uff082008.2, \u798f\u5cf6\uff09
\n37.\t\u4e09\u6728\u3000\u5747, \u5e73\ufa10\u7fa9\u5eb7, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. 3T MRA\u306b\u304a\u3051\u308b\u8133\u52d5\u8108\u7624\u5468\u56f2\u5c0f\u8840\u7ba1\u306e\u63cf\u51fa\u80fd\uff1a3D digital angiography\u3068\u306e\u6bd4\u8f03. \u7b2c36\u56de\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a\uff082008.2, \u6a2a\u6d5c\uff09
\n38.\t\u57ce\u6238\u8f1d\u4ec1, \u4ed6. Quantification of\u3000Regional\u3000Myocardial\u3000Blood\u3000Flow\u3000using\u3000First\u3000Pass\u3000Multidetector-row\u3000 Computed\u3000Tomofraphy\u3000and\u3000Adenosine Triphosphate in Coronary Artery Disease. \u7b2c72\u56de\u65e5\u672c\u5faa\u74b0\u5668\u75c5\u5b66\u4f1a\uff082008.3, \u798f\u5ca1\uff09
\n39.\t\u5009\u7530\u8056, \u57ce\u6238\u8f1d\u4ec1, \u4e95\u4e0a\u7950\u99ac, \u6771\u91ce \u535a, \u671b\u6708\u8f1d\u4e00, \u4ed6. Current Status and Future Direction of Multi Detector-row Computed Tomography for the Integrated Management of Coronary Artery Disease. \u7b2c72\u56de\u65e5\u672c\u5faa\u74b0\u5668\u75c5\u5b66\u4f1a\uff082008.3, \u798f\u5ca1\uff09
\n40.\t\u9577\u5c3e\u5145\u5c55, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u4ed6. Quantification of Myocardial Perfusion by Contrast-enhanced 64-slice MDCT: Characterization of Ischemic Myocardium. \u7b2c72\u56de\u65e5\u672c\u5faa\u74b0\u5668\u75c5\u5b66\u4f1a\uff082008.3, \u798f\u5ca1\uff09
\n41.\t\u9577\u5c3e\u5145\u5c55, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u4ed6. Detection of myocardial ischemia using contrast-enhanced 64-slice MDCT: comparison with stress\/rest myocardial scintigraphy. \u7b2c72\u56de\u65e5\u672c\u5faa\u74b0\u5668\u75c5\u5b66\u4f1a\uff082008.3, \u798f\u5ca1\uff09
\n42.\t\u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e\uff0c\u672c\u7530\u5f18\u6587\uff0c\u4e2d\u5c71\u91cd\u6a39. \u80ba\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u521d\u671f\u6cbb\u7642\u6210\u7e3e. \u7b2c17\u56de\u65e5\u672c\u9ad8\u7cbe\u5ea6\u653e\u5c04\u7dda\u5916\u90e8\u7167\u5c04\u7814\u7a76\u4f1a\uff082008.3, \u6771\u4eac\uff09
\n43.\t\u4e95\u4e0a\u7950\u99ac, \u7d30\u5ddd\u6d69\u5e73, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u6751\u702c\u7814\u4e5f. 3.0T MRI\u3092\u4f7f\u7528\u3057\u305fcine-tagging MRI\u306b\u3088\u308b\u5de6\u5ba4\u5c40\u6240\u58c1\u904b\u52d5\u306e\u5b9a\u91cf\u8a55\u4fa1\u6cd5. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n44.\t\u6850\u5c71\u90c1\u5b50, \u4e09\u6728\u5747, \u83ca\u6c60\u6075\u4e00, \u5e73\u585a\u7fa9\u5eb7, \u671b\u6708\u8f1d\u4e00. \u8133\u8868\u4e09\u6b21\u5143MRI\u306e\u30dc\u30ea\u30e5\u30fc\u30e0\u30ec\u30f3\u30c0\u30ea\u30f3\u30b0\u753b\u50cf\u306b\u304a\u3051\u308b\u4e0d\u900f\u660e\u5ea6\u306e\u6700\u9069\u5316\u306e\u691c\u8a0e. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n45.\t\u6771\u91ce \u535a, \u677e\u672c \u76f4\u4e5f, \u7b20\u4e95 \u7763\u96c4, \u57ce\u6238 \u8f1d\u4ec1, \u4e95\u4e0a \u7950\u99ac, \u5009\u7530 \u8056, \u671b\u6708 \u8f1d\u4e00. \u5fc3\u7b4b\u704c\u6d41\u30b7\u30f3\u30c1\u30b0\u30e9\u30d5\u30a3\u30fc\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u6709\u7528\u6027. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n46.\t\u7af9\u53e3\u5d07, \u57ce\u6238\u502b\u4e4b, \u9ad8\u5c71\u535a\u6a39, \u7af9\u5185\u76f4\u5b50, \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u6751\u4e0a\u5fe0\u53f8, \u83c5\u539f\u656c\u6587. \u975e\u5916\u50b7\u6027\u4e0b\u90e8\u6d88\u5316\u7ba1\u7a7f\u5b54\u306eCT\u6240\u898b. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n47.\t\u5175\u982d\u670b\u5b50, \u6d25\u7530\u5b5d\u6cbb, \u5e73\u7530\u96c5\u662d, \u6751\u4e0a\u6b63\u54f2, \u671b\u6708\u8f1d\u4e00. \u7d4c\u9759\u8108\u6027\u30c0\u30a4\u30ca\u30df\u30c3\u30afCT\u306b\u304a\u3051\u308b\u809d\u5185\u9580\u8108\u304a\u3088\u3073\u809d\u9759\u8108\u306e\u9020\u5f71\u80fd\uff1a\u786c\u5909\u809d\u3068\u975e\u786c\u5909\u809d\u306e\u6bd4\u8f03. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n48.\t\u897f\u5ddd\u6566, \u8d8a\u667a\u8a89\u53f8, \u85e4\u4e95\u5d07, \u671b\u6708\u8f1d\u4e00. \u5f53\u9662\u306b\u304a\u3051\u308b\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n49.\t\u57ce\u6238\u8f1d\u4ec1, \u4ed6. ATP\u8ca0\u8377\u4f75\u7528MDCT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u306e\u5b9a\u91cf\u8a55\u4fa1\u306e\u53ef\u80fd\u6027. \u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n50.\t\u6d25\u7530\u5b5d\u6cbb, \u5175\u982d\u670b\u5b50, \u5e73\u7530\u96c5\u662d, \u6751\u4e0a\u6b63\u54f2, \u7530\u4e2d\u5b8f\u660e, \u671b\u6708\u8f1d\u4e00. 16\u5217MDCT\u306b\u3088\u308b\uff13D CT angiography\u306b\u3088\u308b\u813e\u52d5\u8108\u7624\u306e\u983b\u5ea6\u3000\u7b2c67\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n51.\t\u4e2d\u6751\u8aa0\u6cbb, \u83ca\u6c60\u9686\u5fb3, \u5897\u539f\u3000\u6643, \u5cf0\u96ea\u6d69\u7d9a, \u65b0\u85e4\u6cf0\u53f2. \u5c40\u6240\u8133\u8840\u6d41\u91cf\u5b9a\u91cf\uff1a\u52d5\u8108\u30fb\u9759\u8108\u88dc\u6b63\u6cd5. \u7b2c2\u56de\u8133\u8840\u6d41\u5b9a\u91cf\u6280\u8853\u691c\u8a0e\u4f1a\uff082008.4, \u6a2a\u6d5c\uff09
\n52.\t\u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e. FDG-PET\/CT\u306b\u3088\u308b\u5b9a\u4f4d\u7167\u5c04\u5f8c\u306e\u5c40\u6240\u518d\u767a\u3068\u653e\u5c04\u7dda\u8133\u58ca\u6b7b\u306e\u9451\u5225\u8a3a\u65ad\u306e\u7d4c\u9a13. \u7b2c17\u56de\u65e5\u672c\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u5b66\u4f1a\uff082008.5, \u5948\u826f\uff09
\n53.\t\u6b66\u667a\u6075\uff0c\u5409\u5ca1\u771f\u4e8c\uff0c\u6d66\u5cf6\u96c4\u4ecb\uff0c\u6751\u7530\u7e41\u5229. \u81b5solid pseudo papillary tumor\u306e\u4e00\u4f8b. \u7b2c22\u56de\u8179\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082008.6, \u7b51\u6ce2\uff09
\n54.\t\u5175\u982d\u670b\u5b50, \u83c5\u539f\u656c\u6587, \u6d25\u7530\u5b5d\u6cbb, \u5e73\u7530\u96c5\u662d,\u6751\u4e0a\u6b63\u54f2,\u671b\u6708\u8f1d\u4e00. \u6025\u901f\u306a\u9032\u884c\u3092\u5448\u3057\u305f\u8089\u816b\u69d8\u578b\u814e\u7d30\u80de\u764c\u306e\u4e00\u4f8b. \u7b2c22\u56de\u8179\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082008.6, \u7b51\u6ce2\uff09
\n55.\t\u6771\u91ce \u535a. \u5fc3\u81d3\u9818\u57df\u306b\u304a\u3051\u308b\u9ad8\u78c1\u5834MRI\u88c5\u7f6e\u306e\u6709\u7528\u6027. \u7b2c16\u56de\u65e5\u672cMR Angiography\u7814\u7a76\u4f1a\uff082008.6, \u6771\u4eac\uff09
\n56.\t\u4e95\u4e0a\u7950\u99ac, \u7d30\u5ddd\u6d69\u5e73, \u8f1d\u4ec1, \u5009\u7530\u8056, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u6751\u702c\u7814\u4e5f. 3.0T MRI\u3067\u64ae\u50cf\u3055\u308c\u305fcine-tagging MRI\u306b\u3088\u308b\u5de6\u5ba4strain\u306e\u5b9a\u91cf\u8a55\u4fa1\u6cd5. \u7b2c16\u56de\u65e5\u672cMR Angiography\u7814\u7a76\u4f1a\uff082008.6, \u6771\u4eac\uff09
\n57.\t\u677e\u539f \u4e00\u90ce\u3000\u6c5f\u539f \u79c0\u5b9f\u3000\u8c9e\u672c \u548c\u5f66. 3T MRI\u3092\u7528\u3044\u305f\u672a\u7834\u88c2\u52d5\u8108\u7624\u767a\u898b\u7387\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c16\u56de\u65e5\u672cMR Angiography\u7814\u7a76\u4f1a\uff082008.6, \u6771\u4eac\uff09
\n58.\t\u5e73\u585a\u7fa9\u5eb7, \u4e09\u6728\u3000\u5747, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. \u672a\u7834\u88c2\u8133\u52d5\u8108\u7624\u306b\u304a\u3051\u308b\u691c\u51fa\u80fd\u306e\u691c\u8a0e\uff1a\uff13tesla 3D TOF MRA\u306864-MDCTA\u306e\u6bd4\u8f03. \u7b2c16\u56de\u65e5\u672cMR Angiography\u7814\u7a76\u4f1a\uff082008.6, \u6771\u4eac\uff09
\n59.\t\u6771\u91ce \u535a. \u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3 \u5fb9\u5e95\u6bd4\u8f03 \u5fc3\u81d3\u6838\u533b\u5b66\u3068MRI\/CT MDCT\u3068\u5fc3\u81d3\u6838\u533b\u5b66\u306e\u767a\u5c55. \u7b2c18\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a(2008.6, \u6d25)
\n60.\t\u8d8a\u667a\u8a89\u53f8, \u897f\u5ddd\u6566, \u91cd\u677e\u5065\u5409, \u85e4\u4e95\u5d07, \u671b\u6708\u8f1d\u4e00, \u6c60\u7530\u54f2\u5927, \u897f\u7530\u667a\u4fdd, \u4e39\u53f8\u671b. \u524d\u7acb\u817a\u764c\u5c0f\u7dda\u6e90\u6cbb\u7642\u5f8c\u306b\u809d\u814e\u306b\u8ff7\u5165\u3057\u305f\u7279\u7570\u306aseed migration\u306e\u4e00\u4f8b. \u7b2c5\u56de\u524d\u7acb\u817a\u764c\u5bc6\u5c01\u5c0f\u7dda\u6e90\u6c38\u4e45\u633f\u5165\u6cbb\u7642\u7814\u7a76\u4f1a\uff082008.7, \u6771\u4eac\uff09
\n61.\t\u57ce\u6238\u8f1d\u4ec1. \u5fc3\u7b4b\u8840\u6d41\u5b9a\u91cf\u8a55\u4fa1\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066. \u7b2c67\u56de\u5fc3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082008.7, \u672d\u5e4c\uff09
\n62.\t\u7d30\u5ddd \u6d69\u5e73, \u57ce\u6238 \u8f1d\u4ec1, \u4e95\u4e0a \u7950\u99ac, \u5009\u7530 \u8056, \u6771\u91ce \u535a, \u671b\u6708\u3000\u8f1d\u4e00. \u9045\u5ef6\u9020\u5f71\u306b\u3088\u308b\u5fc3\u7b4b\u6897\u585e\u691c\u51fa\u80fd -CT\u3068MRI\u306e\u6bd4\u8f03-.\u7b2c67\u56de\u5fc3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082008.7, \u672d\u5e4c\uff09
\n63.\t\u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e\uff0c\u4ed9\u6ce2\u8cb4\u654f\uff0c\u4e0a\u6d25\u5b5d\u592a\u90ce. \u8133\u5358\u72ec\u8ee2\u79fb\u3092\u6709\u3059\u308b\uff341-2\uff2e0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u8133\u304a\u3088\u3073\u80ba\u3078\u306e\u5b9a\u4f4d\u7167\u5c04\u306e\u7d4c\u9a13. \u7b2c18\u56de\u65e5\u672c\u9ad8\u7cbe\u5ea6\u653e\u5c04\u7dda\u5916\u90e8\u7167\u5c04\u7814\u7a76\u4f1a\uff082008.7, \u798f\u5ca1\uff09
\n64.\t\u57ce\u6238\u8f1d\u4ec1. MDCT\u306b\u304a\u3051\u308b\u5fc3\u7b4b\u8840\u6d41\u8a55\u4fa1. \u7b2c1\u56deSCMR Japan Chapter \u7814\u7a76\u4f1a\uff082008.8, \u6771\u4eac\uff09
\n65.\t\u57ce\u6238\u8f1d\u4ec1. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u3000MDCT\u3067\u51a0\u52d5\u8108\u3092\u8d85\u3048\u308b\u301c\u5fc3\u7b4b\u9084\u6d41 \u7b2c2\u56deSCCT\u7814\u7a76\u4f1a\uff082008.9, \u6771\u4eac\uff09
\n66.\t\u57ce\u6238\u8f1d\u4ec1. ATP\u8ca0\u8377\u4f75\u7528MDCT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u306e\u5b9a\u91cf\u8a55\u4fa1. \u7b2c2\u56deSCCT\u7814\u7a76\u4f1a\uff082008.9, \u6771\u4eac\uff09
\n67.\t\u5009\u7530\u8056, \u57ce\u6238\u8f1d\u4ec1, \u4e95\u4e0a\u7950\u99ac, \u6771\u91ce \u535a, \u671b\u6708\u8f1d\u4e00, \u4ed6. \u5fc3\u7b4b\u865a\u8840\u3068\u5fc3\u7b4b\u6897\u585e\u306e\u691c\u51fa\u3092\u76ee\u6a19\u306b\u3057\u305fATP \u8ca0\u8377 myocardial perfusion CT \u306e\u53ef\u80fd\u6027. \u7b2c56\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\uff082008.9, \u6771\u4eac\uff09
\n68.\t\u5e73\u585a\u7fa9\u5eb7, \u4e09\u6728\u3000\u5747, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. \u672a\u7834\u88c2\u8133\u52d5\u8108\u7624\u306b\u304a\u3051\u308b\u691c\u51fa\u80fd\u306e\u691c\u8a0e\uff1a3Tesla 3D TOF MRA\u306864-MDCTA\u306e\u6bd4\u8f03. \u7b2c36\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\uff082008.9, \u65ed\u5ddd\uff09
\n69.\t\u77f3\u4e38\u826f\u5e83, \u7530\u53e3\u5343\u8535, \u5c0f\u4e80\u96c5\u5e83, \u68b6\u539f\u8aa0, \u5c71\u4e0b\u606d, \u677e\u6728\u5f18\u91cf, \u66fd\u6211\u90e8\u4e00\u90ce, \u83ca\u6c60\u9686\u5fb3, \u4e2d\u6751\u8aa0\u6cbb, \u5bae\u5ddd\u6b63\u7537. Gd-EOB-DTPA\u9020\u5f71MRI\u306e\u809d\u7d30\u80de\u9020\u5f71\u76f8\u306b\u304a\u3051\u308b\u64ae\u50cf\u958b\u59cb\u6642\u9593\u3068\u809d\u7d30\u80de\u764c\u691c\u51fa\u80fd\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c36\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\uff082008.9, \u65ed\u5ddd\uff09
\n70.\t\u4e95\u4e0a\u7950\u99ac, \u7d30\u5ddd\u6d69\u5e73, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u6751\u702c\u7814\u4e5f. 3.0T MRI\u3092\u4f7f\u7528\u3057\u305f\uff43\uff49\uff4e\uff45\u2212\uff54\uff41\uff47\uff47\uff49n\uff47 MRI\u306b\u3088\u308b\u5de6\u5ba4\u5c40\u6240\u58c1\u904b\u52d5\u306e\u5b9a\u91cf\u8a55\u4fa1\u6cd5. \u7b2c36\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\uff082008.9, \u65ed\u5ddd\uff09
\n71.\t\u5927\u4e0b\u5b97\u4eae, \u6850\u5c71\u90c1\u5b50, \u83ca\u6c60\u6075\u4e00, \u4e09\u6728\u5747, \u671b\u6708\u8f1d\u4e00. pineal cyst apoplexy\u306e\uff11\u4f8b. \u7b2c44\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082008.10, \u90e1\u5c71\uff09
\n72.\t\u5409\u5ca1\u771f\u4e8c\uff0c\u6b66\u667a\u6075\uff0c\u677e\u5742\u667a\u7f8e\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u6d66\u5cf6\u96c4\u4ecb\uff0c\u6751\u7530\u7e41\u5229. \u8f2a\u72b6\u81b5\u3092\u5408\u4f75\u3057\u305f\u81b5\u982d\u90e8\u767a\u751f\u306e\u7c98\u6db2\u7523\u751f\u6027\u81b5\u816b\u760d\u306b\u3064\u3044\u3066. \u7b2c44\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082008.10, \u90e1\u5c71\uff09
\n73.\t\u6771\u91ce\u3000\u535a. \u6559\u80b2\u8b1b\u6f14 \u6838\u533b\u5b66 \u5fc3\u81d3 CT. \u7b2c44\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082008.10, \u90e1\u5c71\uff09
\n74.\t\u897f\u5ddd\u6566, \u8d8a\u667a\u8a89\u53f8, \u91cd\u677e\u5065\u5409, \u85e4\u4e95\u5d07. \u60aa\u6027\u795e\u7d4c\u81a0\u816b\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u306e\u518d\u767a\u5f62\u5f0f\u306e\u691c\u8a0e. \u7b2c21\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u4f1a\uff082008.10, \u672d\u5e4c\uff09
\n75.\t\u7247\u5ca1\u6b63\u660e\uff0c\u6ff1\u672c\u3000\u6cf0\uff0c\u4ed9\u6ce2\u8cb4\u654f\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u672c\u7530\u5f18\u6587\uff0c\u4e2d\u5c71\u91cd\u6a39\uff0c\u9ad8\u5d8b\u6210\u5149. \u5f53\u9662\u306b\u304a\u3051\u308b\u4e73\u623f\u6e29\u5b58\u7642\u6cd5\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c21\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u4f1a\uff082008.10, \u672d\u5e4c\uff09
\n76.\t\u6f81\u8c37\u666f\u5b50, \u5927\u5c4b\u590f\u751f, \u85e4\u4e95\u5d07, \u8352\u6728\u5247\u96c4, \u5149\u68ee\u901a\u82f1, \u5e73\u5ca1\u771f\u5bdb. \u81b5\u764c\u306e\u30b2\u30e0\u30b7\u30bf\u30d3\u30f3\u540c\u6642\u4f75\u7528\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u7b2c\uff12\u76f8\u8a66\u9a13\u306b\u304a\u3051\u308b\u6d88\u5316\u5668\u6bd2\u6027\u3068\u7dda\u91cf\u5206\u5e03. \u7b2c21\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u4f1a\uff082008.10, \u672d\u5e4c\uff09
\n77.\t\u8d8a\u667a\u8a89\u53f8, \u6c60\u7530\u54f2\u5927, \u897f\u7530\u667a\u4fdd, \u4e39\u53f8\u671b, \u91cd\u677e\u5065\u5409, \u897f\u5ddd\u6566, \u85e4\u4e95\u5d07, \u671b\u6708\u8f1d\u4e00. \u524d\u7acb\u817a\u764c\u5c0f\u7dda\u6e90\u6cbb\u7642\u5f8c\u306b\u809d\u814e\u306b\u8ff7\u5165\u3057\u305f\u7279\u7570\u306aseed migration\u306e\u4e00\u4f8b. \u7b2c21\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u4f1a\uff082008.10, \u672d\u5e4c\uff09
\n78.\t\u7247\u5ca1\u6b63\u660e\uff0c\u6ff1\u672c\u3000\u6cf0\uff0c\u4ed9\u6ce2\u8cb4\u654f\uff0c\u672c\u7530\u5f18\u6587\uff0c\u4e2d\u5c71\u91cd\u6a39\uff0c\u9152\u4e95\u4f38\u4e5f. \u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u6c38\u4e45\u633f\u5165\u8853\u306b\u304a\u3051\u308b\u6025\u6027\u671f\u5c3f\u8def\u5408\u4f75\u75c7\u306e\u30ea\u30b9\u30af\u56e0\u5b50\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c21\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u4f1a\uff082008.10, \u672d\u5e4c\uff09
\n79.\t\u6ff1\u672c\u3000\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e\uff0c\u4ed9\u6ce2\u8cb4\u654f\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u4e0a\u6d25\u5b5d\u592a\u90ce\uff0c\u672c\u7530\u5f18\u6587\uff0c\u4e2d\u5c71\u91cd\u6a39. \u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u3092\u65bd\u884c\u3057\u305fIII\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306e\u6cbb\u7642\u6210\u7e3e\u3068\u518d\u767a\u5f62\u5f0f. \u7b2c21\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u4f1a\uff082008.10, \u672d\u5e4c\uff09
\n80.\t\u9577\u5c3e\u5145\u5c55, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u5fb3\u6c38\u4f38\u5b50, \u6751\u702c\u7814\u4e5f. 64\u5217MDCT\u306e\u5fc3\u7b4b\u30a4\u30e1\u30fc\u30b8\u306b\u3088\u308b\u6025\u6027\u51a0\u75c7\u5019\u7fa4\u306e\u865a\u8840\u8a55\u4fa1\uff1a\u5b89\u9759\u6642\u5fc3\u7b4b\u8840\u6d41\u30b7\u30f3\u30c1\u3068\u306e\u6bd4\u8f03. \u7b2c48\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\uff082008.10, \u5343\u8449\uff09<\/p>\n

<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/p>\n

81.\t\u5ddd\u53e3\u76f4\u4eba, \u4e95\u624b\u9999\u5948, \u6d25\u7530\u5b5d\u6cbb, \u6850\u5c71\u90c1\u5b50, \u5009\u7530\u3000\u8056, \u6771\u91ce\u3000\u535a, \u83c5\u539f\u656c\u6587, \u4e09\u6728\u3000\u5747, \u671b\u6708. \u5076\u7136\u767a\u898b\u3055\u308c\u305f\u80ba\u5c0f\u7d30\u80de\u764c\u306e2\u4f8b. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n82.\t\u8d77\u585a\u9999\u5b50, \u5175\u982d\u670b\u5b50, \u5e73\u7530\u96c5\u662d, \u6751\u4e0a\u3000\u6b63\u54f2, \u7d30\u5ddd\u6d69\u5e73, \u57ce\u6238\u8f1d\u4ec1, \u83ca\u6c60\u6075\u4e00, \u83c5\u539f\u656c\u6587, \u671b\u6708\u8f1d\u4e00, \u5c71\u672c\u82f1\u8cc7, \u5150\u5cf6\u3000\u6d0b, \u5c0f\u6797\u5c55\u7ae0. \u80c3\u77f3\u306b\u3088\u308b\u5c0f\u8178\u30a4\u30ec\u30a6\u30b9\u306e1\u4f8b. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n83.\t\u9752\u91ce\u7965\u53f8, \u4e95\u4e0a\u6b66, \u9152\u4e95\u4f38\u4e5f, \u9ad8\u6a4b\u5fe0\u7ae0, \u5c0f\u7530\u7701\u543e, \u4e0a\u6d25\u5b5d\u592a\u90ce, \u83c5\u7530\u6210\u7d00. \u9020\u5f71PET-CT\u3092\u7528\u3044\u305f\u5927\u8178\u304c\u3093\u306e\u8853\u524d\u75c5\u671f\u8a3a\u65ad\u80fd\uff5e\u6df1\u9054\u5ea6\u8a3a\u65ad\u3068\u8179\u819c\u64ad\u7a2e\u306e\u8a3a\u65ad\u80fd\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff5e. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n84.\t\u4e0a\u6d25\u5b5d\u592a\u90ce\uff0c\u6ff1\u672c\u3000\u6cf0\uff0c\u4ed9\u6ce2\u8cb4\u654f\uff0c\u5c0f\u7530\u5c1a\u543e\uff0c\u9ad8\u6a4b\u5fe0\u7ae0\uff0c\u9752\u91ce\u7965\u53f8\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u4e95\u4e0a\u3000\u6b66\uff0c\u83c5\u7530\u6210\u7d00\uff0c\u7247\u5ca1\u6b63\u660e. \u80ba\u5b9a\u4f4d\u7167\u5c04\u5f8c\u306e\u5c40\u6240\u518d\u767a\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n85.\t\u6b66\u667a\u6075\uff0c\u5409\u5ca1\u771f\u4e8c\uff0c\u6d66\u5cf6\u96c4\u4ecb\uff0c\u6751\u7530\u7e41\u5229. \u7279\u7570\u306a\u9032\u5c55\u5f62\u5f0f\u3092\u5448\u3057\u305f\u80c6\u56a2\u764c\u306e1\u4f8b. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n86.\t\u4ed9\u6ce2\u8cb4\u654f, \u7247\u5ca1\u6b63\u660e, \u6ff1\u672c\u3000\u6cf0, \u4e0a\u6d25\u5b5d\u592a\u90ce, \u5c0f\u7530\u5c1a\u543e, \u9752\u91ce\u7965\u53f8, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u4e95\u4e0a\u3000\u6b66, \u83c5\u7530\u6210\u7d00. \u524d\u7acb\u817a\u764c\u6c38\u4e45\u633f\u5165\u8853\u5f8c\u306e\u6025\u6027\u671f\u5c3f\u8def\u5408\u4f75\u75c7\u306e\u767a\u751f\u5371\u967a\u56e0\u5b50\u306b\u3064\u3044\u3066. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n87.\t\u7530\u53e3\u5343\u85cf, \u5c0f\u4e80\u96c5\u5e83, \u68b6\u539f\u8aa0, \u5c71\u4e0b\u606d, \u677e\u6728\u5f18\u91cf, \u66fd\u6211\u90e8\u4e00\u90ce, \u77f3\u4e38\u826f\u5e83, \u83ca\u6c60\u9686\u5fb3, \u4e2d\u6751\u8aa0\u6cbb, \u5bae\u5ddd\u6b63\u7537. \u9aa8\u76e4\u5185solitary fibrous tumor\u306e1\u4f8b. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n88.\t\u5c0f\u5ca9\u539f\u5143, \u8d8a\u667a\u8a89\u53f8, \u897f\u5ddd\u6566, \u85e4\u4e95\u5d07, \u4e95\u4e0a\u7950\u99ac, \u4e2d\u5cf6\u76f4\u7f8e, \u4e09\u6728\u5747, \u83c5\u539f\u656c\u6587, \u671b\u6708\u8f1d\u4e00. \u65e9\u671f\u306b\u9aa8\u8ee2\u79fb\u3092\u6765\u3057\u305f\u4e73\u623f\u539f\u767aadenoidcystic carcinoma\u306e\u4e00\u4f8b. \u7b2c110\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.6, \u51fa\u96f2)
\n89.\t\u5009\u7530\u8056, \u57ce\u6238\u8f1d\u4ec1, \u4e95\u4e0a\u7950\u99ac, \u6771\u91ce \u535a, \u671b\u6708\u8f1d\u4e00, \u4ed6. 64 \u5217 CT\u306b\u3088\u308b\u5fc3\u6a5f\u80fd\u8a55\u4fa1\u304c\u6709\u7528\u3067\u3042\u3063\u305f\u51a0\u52d5\u8108\u30d0\u30a4\u30d1\u30b9\uff0b Dor \u624b\u8853\u306e \uff11 \u75c7\u4f8b. \u7b2c92\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5408\u540c\u5730\u65b9\u4f1a\uff082008.6, \u4e0b\u95a2\uff09
\n90.\t\u771f\u934b\u7531\u9999, \u6c5f\u539f \u79c0\u5b9f, \u8c9e\u672c\u548c\u5f66, \u4ed6. \u8179\u90e8\u5927\u52d5\u8108\u5468\u56f2\u306b\u4f4e\u8f1d\u5ea6\u30a8\u30b3\u30fc\u3092\u8a8d\u3081\u305f2\u75c7\u4f8b. \u7b2c81\u56de\u65e5\u672c\u8d85\u97f3\u6ce2\u533b\u5b66\u4f1a\uff082008.10, \u677e\u5c71\uff09
\n91.\t\u6d66\u5cf6\u96c4\u4ecb\uff0c\u5409\u5ca1\u771f\u4e8c\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u677e\u5742\u667a\u7f8e, \u6b66\u667a\u3000\u6075\uff0c\u6751\u7530\u3000\u7e41\u5229, \u85e4\u4e95\u3000\u5143\u5ee3\u5f53\u9662\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u764c\u3078\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u6210\u7e3e\u306e\u691c\u8a0e. \u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n92.\t\u4e2d\u5cf6\u76f4\u7f8e\uff0c\u5175\u982d\u670b\u5b50\uff0c\u5e73\u7530\u96c5\u662d\uff0c\u6751\u4e0a\u6b63\u54f2, \u4e95\u624b\u9999\u5948\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u83ca\u6c60\u6075\u4e00, \u4e09\u6728\u3000\u5747\uff0c\u6d25\u7530\u5b5d\u6cbb\uff0c\u671b\u6708\u8f1d\u4e00, \u6749\u4e0b\u535a\u57fa, \u6cb3\u5185\u5bdb\u6cbb. \u30a4\u30ec\u30a6\u30b9\u3067\u767a\u75c7\u3057\u305f\u8ee2\u79fb\u6027\u5c0f\u8178\u764c\u306e1 \u4f8b. .\u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n93.\t\u4e95\u4e0a\u7950\u99ac\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u5c0f\u5ca9\u539f\u5143\uff0c\u8d77\u585a\u9999\u5b50, \u30ab\u30f3\u30b6\u30fb\u30ec\u30cd\u30fb\u30a8\u30d7\u30f3\u30b6\uff0c\u57ce\u6238\u3000\u8f1d\u4ec1\uff0c\u5009\u7530\u3000\u8056, \u9577\u5c3e\u5145\u5c55\uff0c\u6771\u91ce\u3000\u535a\uff0c\u671b\u6708\u8f1d\u4e00. 3.0T MRI\u306b\u3088\u308b\u5fc3\u7b4bstrain\u306e\u5b9a\u91cf\u8a55\u4fa1\u306e\u8a66\u307f. \u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n94.\t\u4e0a\u6d25\u5b5d\u592a\u90ce\uff0c\u4e95\u4e0a\u3000\u6b66\uff0c\u5c0f\u7530\u5c1a\u543e\uff0c\u9ad8\u6a4b\u5fe0\u7ae0\uff0c\u9752\u91ce\u7965\u53f8\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587, \u65e5\u6d66\u660c\u76f4. \u5b50\u5bae\u817a\u8089\u816b\u306e\u4e00\u4f8b. \u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n95.\t\u57ce\u6238\u502b\u4e4b, \u7af9\u5185\u76f4\u5b50, \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u6751\u4e0a\u5fe0\u53f8, \u7af9\u53e3\u5d07, \u6c34\u4e4b\u6c5f\u77e5\u54c9. \u5b50\u5bae\u764c\u8089\u816b\u306e2\u4f8b. \u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n96.\t\u6b66\u667a\u6075\uff0c\u5409\u5ca1\u771f\u4e8c\uff0c\u677e\u5742\u667a\u7f8e\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u6d66\u5cf6\u96c4\u4ecb\uff0c\u6751\u7530\u7e41\u5229. \u7279\u7570\u306a\u5f62\u614b\u3092\u793a\u3057\u305f\u809d\u5185\u80c6\u7ba1\u7d30\u80de\u764c\u306e1\u4f8b. \u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n97.\t\u7530\u53e3\u5343\u85cf, \u5c0f\u4e80\u96c5\u5e83, \u68b6\u539f\u8aa0, \u5c71\u4e0b\u606d, \u677e\u6728\u5f18\u91cf, \u66fd\u6211\u90e8\u4e00\u90ce, \u77f3\u4e38\u826f\u5e83, \u83ca\u6c60\u9686\u5fb3, \u4e2d\u6751\u8aa0\u6cbb, \u5bae\u5ddd\u6b63\u7537, \u4ed6. \u81b5\u764c\u624b\u8853\u4f8b\u306b\u304a\u3051\u308bPET\/CT\u306e\u8a3a\u65ad\u80fd. \u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)
\n98.\t\u85e4\u4e95\u3000\u5d07. \u6559\u80b2\u30bb\u30df\u30ca\u30fc\u300c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u7dcf\u8ad6\u300d\u7b2c111\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2008.11, \u9ad8\u677e)<\/p>\n

<\/a>\u25a0<\/span> \u8b1b\u6f14<\/strong><\/p>\n

1.\t\u897f\u5ddd\u3000\u6566. \u8ee2\u79fb\u6027\u8133\u816b\u760d\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u306b\u3064\u3044\u3066 \u2015 \u5168\u8133\u7167\u5c04\u306e\u7acb\u5834\u304b\u3089 \u2015. \u8ee2\u79fb\u6027\u8133\u816b\u760d\u3092\u8003\u3048\u308b\u4f1a\u611b\u5a9b\uff082008.1, \u677e\u5c71\u5e02\uff09
\n2.\t\u5c71\u672c\u5c1a\u5e78. \u653e\u5c04\u7dda\u306e\u57fa\u790e\u77e5\u8b58. \u611b\u5a9b\u30a8\u30cd\u30eb\u30ae\u30fc\u3092\u8003\u3048\u308b\u4f1a\uff082008.1, \u677e\u5c71\u5e02\uff09
\n3.\t\u5bae\u5ddd\u6b63\u7537. PET-CT\u3067\u304c\u3093\u306f\u3069\u3053\u307e\u3067\u308f\u304b\u308b\u306e\u304b. \u611b\u5a9b\u770c\u516c\u958b\u8b1b\u5ea7\uff082008.1, \u5b87\u548c\u753a\uff09
\n4.\t\u671b\u6708\u8f1d\u4e00\u3000\u30de\u30eb\u30c1\u30e2\u30c0\u30ea\u30c6\u30a3\u30fc\u6642\u4ee3\u306b\u304a\u3051\u308b\u5fc3\u81d3\u6838\u533b\u5b66\u8a3a\u65ad\u306b\u3064\u3044\u3066\u3000\u7b2c14\u56de\u5bae\u5d0eRI\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u3000\uff082008.1,\u3000\u5bae\u5d0e\u5e02\uff09
\n5.\t\u671b\u6708\u8f1d\u4e00\u3000\u5fc3\u75be\u60a3\u306b\u304a\u3051\u308bCT\u3068\u6838\u533b\u5b66\u8a3a\u65ad\u306b\u3064\u3044\u3066\u3000\u7b2c19\u56de\u706b\u306e\u56fdRI\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u3000\uff082008.2,\u3000\u718a\u672c\u5e02\uff09
\n6.\t\u7530\u4e2d\u5b8f\u660e. \u6700\u8fd1\u306eInterventional Radiology(IVR). \u7b2c10\u56de\u6771\u4e88\u653e\u5c04\u7dda\u79d1\u533b\u4f1a(2008.2, \u4eca\u6cbb\u5e02)
\n7.\t\u671b\u6708\u8f1d\u4e00\u3000\u5fc3\u81d3\uff23\uff34\u306e\u904e\u53bb\u30fb\u73fe\u5728\u30fb\u672a\u6765\u3000\u3000\u7b2c10\u56de\u305b\u3068\u3046\u3061\u5fc3\u81d3CT\u52c9\u5f37\u4f1a\u3000\uff082008.2.16\u3000\u677e\u5c71\u5e02\uff09
\n8.\t\u83ca\u6c60\u6075\u4e00. \u5faa\u74b0\u5668Dr\u306e\u305f\u3081\u306eMRI\u306e\u57fa\u790e. \u611b\u5a9b\u5fc3\u81d3MRI\u7814\u7a76\u4f1a\uff082008.3, \u677e\u5c71\u5e02\uff09
\n9.\t\u6771\u91ce\u3000\u535a. \u30de\u30eb\u30c1\u30e2\u30c0\u30ea\u30c6\u30a3\u5fc3\u81d3\u89e3\u6790. \u7b2c22\u56de\u5168\u56fd\u5faa\u74b0\u5668\u64ae\u5f71\u7814\u7a76\u4f1a\u5b66\u8853\u5927\u4f1a\uff082008.4, \u6a2a\u6d5c\u5e02\uff09
\n10.\t\u5c71\u672c\u5c1a\u5e78. \u6c5a\u67d3\u3092\u4f34\u3063\u305f\u91cd\u75c7\u5916\u50b7\u60a3\u8005\u306e\u53d6\u6271. \u4f50\u8cc0\u300c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u57fa\u790e\u8b1b\u5ea7\u2160\u300d\uff082008.6, \u5510\u6d25\u5e02\uff09
\n11.\t\u671b\u6708\u8f1d\u4e00\u3000\u611b\u5a9b\u306e\u304c\u3093\u8a3a\u7642\u3000\u65e5\u672c\u6838\u533b\u5b66\u6280\u8853\u5b66\u4f1a\u7b2c20\u56de\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\u3000\uff082008.6,\u3000\u65b0\u5c45\u6d5c\u5e02\uff09
\n12.\t\u5c71\u672c\u5c1a\u5e78. \u673a\u4e0a\u6f14\u7fd2\u3000\u60f3\u5b9a\u4e8b\u6545\u306e\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642. \u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\uff62\u611b\u5a9b\u30d5\u30a9\u30fc\u30e9\u30e0\uff63\uff082008.\uff17, \u677e\u5c71\u5e02\uff09
\n13.\t\u4ed9\u6ce2\u82b3\u6a39. \u6280\u5e2b\u306e\u305f\u3081\u306e\u300c\u77e5\u3063\u3066\u304a\u304d\u305f\u3044\u80f8\u5199\u30fbCT\u306e\u898b\u65b9, \u8aad\u307f\u65b9\u300d\u6771\u4e88\u652f\u90e8\u751f\u7406\u691c\u67fb\u5206\u79d1\u4f1a\uff082008.7, \u4eca\u6cbb\u5e02\uff09
\n14.\t\u5c71\u672c\u5c1a\u5e78. \u6c5a\u67d3\u3092\u4f34\u3063\u305f\u91cd\u75c7\u5916\u50b7\u60a3\u8005\u306e\u53d6\u6271. \u5317\u6d77\u9053\u300c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u57fa\u790e\u8b1b\u5ea7\u2160\u300d\uff082008.9, \u672d\u5e4c\u5e02\uff09
\n15.\t\u5c71\u672c\u5c1a\u5e78. \u6c5a\u67d3\u3092\u4f34\u3063\u305f\u91cd\u75c7\u5916\u50b7\u60a3\u8005\u306e\u53d6\u6271. \u611b\u5a9b\u300c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u57fa\u790e\u8b1b\u5ea7\u2160\u300d\uff082008.10, \u6771\u6e29\u5e02\uff09
\n16.\t\u671b\u6708\u8f1d\u4e00\u3000\u5fc3\u81d3\u6838\u533b\u5b66\u306b\u3064\u3044\u3066\u3000\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u30fb\u4e2d\u56fd\u56db\u56fd\u5730\u57df\u5225\u6559\u80b2\u7814\u4fee\u4f1a\u3000\uff082008.10,\u3000\u5ca1\u5c71\u5e02\uff09
\n17.\t\u671b\u6708\u8f1d\u4e00\u3000\u5fc3\u81d3CT\u3067\u3053\u3053\u307e\u3067\u308f\u304b\u308b\u3000\u7b2c29\u56de\u5ca1\u5c71\u8d64\u5341\u5b57\u75c5\u9662\u5faa\u74b0\u5668\u30bb\u30f3\u30bf\u30fc\u958b\u8a2d\u8a18\u5ff5\u8b1b\u6f14\u4f1a\u3000\uff082008.10,\u3000\u5ca1\u5c71\u5e02\uff09
\n18.\t\u7247\u5ca1\u6b63\u660e. Intra-operative Planning for Localized Prostate Cancer in Shikoku Cancer Center Hospital. \u7b2c\uff12\u56de\u300c\u524d\u7acb\u817a\u304c\u3093\u6c38\u4e45\u633f\u5165\u5bc6\u5c01\u5c0f\u7dda\u6e90\u6cbb\u7642\u7814\u7a76\u4f1a\u300d\uff082008.11, \u5927\u962a\uff09<\/p>\n

<\/a>\u25a0<\/span> \u7814\u7a76\u52a9\u6210\u30fb\u4ed6<\/strong><\/p>\n

\u6587\u90e8\u79d1\u5b66\u7701\u79d1\u5b66\u7814\u7a76\u8cbb\u88dc\u52a9\u91d1\u3000\u5e73\u621019\u5e74\u5ea6-\u5e73\u621020\u5e74\u5ea6
\n\u57fa\u76e4\u7814\u7a76\uff08C\uff09\u8ab2\u984c\u756a\u53f719591422
\n\u6771\u91ce\u535a
\n3\u30c6\u30b9\u30e9\u78c1\u6c17\u5171\u9cf4\u88c5\u7f6e\u3092\u7528\u3044\u305f\u5fc3\u81d3\u30bf\u30ae\u30f3\u30b0\u64ae\u50cf\u306e\u81ea\u52d5\u89e3\u6790\u30b7\u30b9\u30c6\u30e0\u306e\u958b\u767a<\/p>\n

\u6587\u90e8\u79d1\u5b66\u7701\u79d1\u5b66\u7814\u7a76\u8cbb\u88dc\u52a9\u91d1\u3000\u5e73\u621020\u5e74\u5ea6\u301c\u5e73\u621021\u5e74\u5ea6
\n\u57fa\u76e4\u7814\u7a76\uff08C\uff09\u8ab2\u984c\u756a\u53f720591447
\n\u671b\u6708\u8f1d\u4e00
\n\u30de\u30eb\u30c1\u30b9\u30e9\u30a4\u30b9CT\u3092\u7528\u3044\u305f\u201c\u6a19\u6e96\u7684\u51a0\u52d5\u8108\u652f\u914d\u9818\u57df\u8868\u793a\u30d6\u30eb\u30ba\u30a2\u30a4\u30de\u30c3\u30d7\u201d\u306e\u4f5c\u6210<\/p>\n","protected":false},"template":"","class_list":["post-180","results","type-results","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/results\/180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/results"}],"about":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/types\/results"}],"wp:attachment":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/media?parent=180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}